LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD).

Publication

Author(s):

Han SH, Zhou J, Saghayam S, Vanar S, Phanuphak N, Chen YM, Sirisanthana T, Sungkanuparph S, Lee CK, Pujari S, Li PC, Oka S, Saphonn V, Zhang F, Merati TP, Law MG, Choi JY; TREAT Asia HIV Observational Database.

Pub Title:

Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD).

Pub Date:

Apr 27 2011

Pub Region(s):

Asia-Pacific

Journal Issue:

6

Page Number:
475-84

Journal:

Title: 
Endocrinology Journal
Link: 
https://www.jstage.jst.go.jp/article/endocrj/58/6/58_K10E-407/_article

PubMed: 21521929
Pub PDF: PDF icon 58_475.pdf

Abstract
The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5%) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years [stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years]. In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p<0.001, > 2 years vs. no experience: OR 14.92, p<0.001), use of PI (> 2.6 years vs. no experience: OR 0.26, p<0.001), and total duration of cART (> vs. ≤ 3.8 years: OR 4.84, p<0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region.

PMID: 21521929 [PubMed - indexed for MEDLINE]

PMCID: PMC3329967

 

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Han SH, Zhou J, Saghayam S, Vanar S, Phanuphak N, Chen YM, Sirisanthana T, Sungkanuparph S, Lee CK, Pujari S, Li PC, Oka S, Saphonn V, Zhang F, Merati TP, Law MG, Choi JY; TREAT Asia HIV Observational Database. Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocr J. 2011;58(6):475-84. Epub 2011 Apr 27. PubMed PMID: 21521929; PubMed Central PMCID: PMC3329967.